Fred Hutchinson Cancer Research Center spin-off Enodar Biologic has launched its True Discovery genomic data-analysis services for the pharmaceutical and biotechnology industries.
Components of the service, which comprises patent-pending technology licensed from the Fred Hutchinson Cancer Research Center, are indented to “reduce genomic data backlogs, to provide an independent means to verify and validate biomarker discoveries, and to identify a higher number of quality biomarkers for investigation,” Enodar said this week.
Zymark has begun rolling out its Staccato Cell Station Assay, a workstation for automating cell-based assays that is claims to be half the size of existing systems.
The pre-assembled system requires 15 square feet of laboratory space to process batches of 40 plates in either 96 or 384 format, according to Zymark, which added that the setup is designed to work with cell-based assays including apoptosis, necrosis, in vitro cytotoxicity, antagonist assays, and channel assays.
The Staccato includes the Twister II platemover for loading microplates and disposable tips; a RapidPlate liquid handler with on-line fill capability; a Zymark-built 44-position robot-accessible incubator with automated delidding; a BioTek 405 washer; and a bar code scanner. It also includes a software adapter for a variety of user-provided compact multi-mode readers, Zymark said.
According to the company, researchers are able to operate the system from a graphical user interface by selecting the methods they wish to run on the touch screen monitor. A Class II biological enclosure and a shaking version of the incubator are available as options.